Morphic Holding, Inc. (MORF)

Market Cap	1.55B
Revenue (ttm)	70.81M
Net Income (ttm)	-59.04M
Shares Out	41.52M
EPS (ttm)	-1.55
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	570,221
Open	37.33
Previous Close	37.63
Day's Range	35.89 - 37.64
52-Week Range	19.23 - 49.24
Beta	1.18
Analysts	Buy
Price Target	60.18 (+61.69%)
Earnings Date	May 2, 2023

About MORF

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avß6 for the treatment of fibroti...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 27, 2019
• Employees: 103
• Stock Exchange: NASDAQ
• Ticker Symbol: MORF

Financial Performance

In 2022, MORF's revenue was $70.81 million, an increase of 257.72% compared to the previous year's $19.79 million. Losses were -$59.04 million, -38.20% less than in 2021.

Analyst Forecast

According to 15 analysts, the average rating for MORF stock is "Buy." The 12-month stock price forecast is $60.18, which is an increase of 61.69% from the latest price.

Price Target

$60.18

(61.69% upside)

Analyst Consensus: Buy